<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="33618">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02113319</url>
  </required_header>
  <id_info>
    <org_study_id>CHUpromoteur2006-08</org_study_id>
    <nct_id>NCT02113319</nct_id>
  </id_info>
  <brief_title>Study to Assess Dasatinib in Patients With Core Binding Factors Acute Myelogenous Leukemia</brief_title>
  <acronym>DasaCBF</acronym>
  <official_title>An Open-Label, Multicenter, Phase II Study to Assess Dasatinib in Patients With Core Binding Factors Acute Myelogenous Leukemia Refractory to Conventional Chemotherapy or in Molecular Relapse. Intergroupe Français Des leucémie aiguë myéloblastique</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Angers</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Angers</source>
  <oversight_info>
    <authority>France: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In patients with Core Binding Factors Acute Myelogenous Leukemia, the level of Minimal
      Residual Disease after chemotherapy is predictive of relapse. The relapse risk is also
      increased in case of mutations of receptors tyrosine kinase. For patients with a high
      Minimal Residual Disease  level at the end of consolidation or in molecular relapse,
      maintenance by the inhibitor dasatinib is proposed.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>measure relapse-free survival</measure>
    <time_frame>4 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Acute Myelogenous Leukemia</condition>
  <arm_group>
    <arm_group_label>dasatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dasatinib</intervention_name>
    <description>dasatinib 50 mg and 20 mg During one year</description>
    <arm_group_label>dasatinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient presenting de novo or secondary Core Binding Factors Acute Myelogenous
             Leukemia

          -  Patient in first and presenting one of following criteria:

          -  &quot;Resistant&quot; Patient: decrease of less than 3 log of the Acute Myelogenous Leukemia
             transcript level in the bone marrow after 2 consolidations

          -  Patient in &quot; molecular relapse &quot;: increase of of more than 1 log of the Core Acute
             Myelogenous Leukemia transcript level on two successive marrow samples

        Exclusion Criteria:

          -  Woman of childbearing potential

          -  Concurrent incurable malignacy other than Acute Myelogenous Leukemia
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Angers</city>
        <zip>49 933</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2009</verification_date>
  <lastchanged_date>April 11, 2014</lastchanged_date>
  <firstreceived_date>March 5, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Core Binding Factors</keyword>
  <keyword>Acute Myelogenous Leukemia refractory to conventional chemotherapy</keyword>
  <keyword>molecular relapse</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dasatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
